<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6724</article-id>
      <article-id pub-id-type="doi">10.51847/qZS08gqJvC</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pharmacokinetics of Amikacin in Eye Media Using Various Drugs</article-title>
      </title-group>
                  <pub-date pub-type="epub">
        <day>28</day>
        <month>07</month>
        <year>2023</year>
      </pub-date>
      <volume>14</volume>
      <issue>3</issue>
      <fpage>107</fpage>
      <lpage>113</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>In the treatment of eye diseases caused by various bacteria, it is extremely important to achieve a therapeutic dose of the drug in the affected organ on time. Otherwise, antibiotic resistance may develop. However, the situation is complicated by the fact that the permeability of the blood-ocular barrier of the inflamed eye drops significantly, and the therapeutic dose of most antibiotics is reached only within 3-4 days of treatment. This article uses the example of laboratory animals (rabbits) to study ways to increase the permeability of the blood-ocular barrier. To do this, individuals who have been injected with a strain of microorganisms Staphylococcus aureus are treated with the antibiotic amikacin. The effect of drugs Cerebrolysin, nicotinic acid, and Selenpropionics on the rate of penetration of the antibiotic into the affected organ is being studied. The course of the disease and the general well-being of rabbits are monitored, and the biochemical and hematological parameters of blood are analyzed. In addition, on the first and fifth day of the course of the disease, the concentration of amikacin in biological fluids was determined: in the blood serum and the intraocular fluid.</p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>